Your browser doesn't support javascript.
loading
Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.
Regnault, Antoine; Pompilus, Farrah; Ciesluk, Anna; Mazerolle, Flora; Bejar, Rafael; Fram, Robert J; Faller, Douglas V; Marquis, Patrick; Bell, Jill A.
Afiliación
  • Regnault A; Modus Outcomes, 4 Place Amédée Bonnet, 69002, Lyon, France. antoine.regnault@modusoutcomes.com.
  • Pompilus F; Modus Outcomes, Cambridge, MA, USA.
  • Ciesluk A; Modus Outcomes, Cambridge, MA, USA.
  • Mazerolle F; Modus Outcomes, 4 Place Amédée Bonnet, 69002, Lyon, France.
  • Bejar R; Moores Cancer Center, UC San Diego - MDS Center of Excellence, San Diego, CA, USA.
  • Fram RJ; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Faller DV; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Marquis P; Modus Outcomes, Cambridge, MA, USA.
  • Bell JA; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
J Patient Rep Outcomes ; 5(1): 60, 2021 Jul 20.
Article en En | MEDLINE | ID: mdl-34283303
ABSTRACT

PURPOSE:

Physical functioning and fatigue are key patient concerns in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). The objective of this research was to generate supportive quantitative evidence for modular physical functioning and fatigue measures based on the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and a customized selection of 10 supplemental items from the EORTC Item Library.

METHODS:

The 40 items were completed online cross-sectionally by 51 patients (higher risk [HR] MDS 53%; CMML 26%; AML 10%). Psychometric analyses based on Rasch measurement theory (RMT) were conducted on the QLQ-C30 physical functioning and fatigue domains as well as measures combining QLQ-C30 and supplemental items. A measure of anemia-related symptoms composed of QLQ-C30 and supplemental items covering fatigue, dyspnea, and dizziness was also investigated.

RESULTS:

The QLQ-C30 physical functioning and fatigue domains showed good targeting to the sample and adequate reliability, with few conceptual gaps identified. Combining the QLQ-C30 and supplemental physical functioning and fatigue items improved the conceptual coverage and the reliability of the measures. The patient-reported anemia-related symptom measure showed good measurement performance, underpinned by a clinically meaningful characterization of severity of these symptoms over a spectrum, starting with fatigue, then dyspnea, and finally dizziness (most severe).

CONCLUSION:

The modular measurement approach of combining EORTC QLQ-C30 and Item Library offers a promising pragmatic solution to the measurement of physical functioning and fatigue, as well as anemia-related symptoms in clinical trials conducted in HR MDS, CMML, and AML.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Patient Rep Outcomes Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Patient Rep Outcomes Año: 2021 Tipo del documento: Article País de afiliación: Francia